8 Papers
19 Citations
L. M. Weiner is an academic researcher from Johnson & Johnson Pharmaceutical Research and Development. The author has contributed to research in topics: Pancreatic cancer & Fibroblast activation protein, alpha. The author has an hindex of 3, co-authored 8 publications.
Chat about Author
Papers
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
Steven J. Cohen,Linus Ho,Sulabha Ranganathan,James L. Abbruzzese,R. Katherine Alpaugh,Mary Beard,Nancy L. Lewis,Susan McLaughlin,Andre Rogatko,Juan J. Perez-Ruixo,Amanda M. Thistle,Tom Verhaeghe,Hao Wang,L. M. Weiner,John J. Wright,Gary R. Hudes,N. J. Meropol +16 more
TL;DR: Although treatment with R115777 resulted in partial inhibition of FTase activity in mononuclear cells, it did not exhibit single-agent antitumor activity in patients with previously untreated metastatic pancreatic cancer.
175
A randomized phase II and coagulation study of bevacizumab alone or with docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma
Igor Astsaturov,Neal J. Meropol,R. K. Alpaugh,Jonathan D. Cheng,Nancy L. Lewis,Mary Beard,Andre Rogatko,Zhiheng Xu,L. M. Weiner,Steven J. Cohen +9 more
TL;DR: This randomized phase II study of bevacizumab (BEV) alone or with docetaxel (DOC) in patients with previously treated metastatic pancreatic adenocarcinoma to investigate their clinical activity and interaction with coagulation.
10
Phase II pharmacodynamic study of the fibroblast activation protein inhibitor Val-boro-Pro in patients with metastatic colorectal cancer
Jonathan D. Cheng,Steven J. Cohen,B. Stzempkowski-Brun,K. Magalong,V. J. Christiansen,P. A. McKee,R. K. Alpaugh,H. Lee,L. M. Weiner,Neal J. Meropol +9 more
TL;DR: Val-boro-Pro 200 μg orally twice daily is biologically active and well-tolerated, with toxicities likely related to cytokine upregulation, and the selectivity of FAP expression for tumor fibroblasts provides a unique opportunity to investigate and manipulate stromal contributions to tumor growth and invasion.
4
Phase I clinical and pharmacokinetic study of the farnesyl transferase inhibitor BMS-214662 administered intravenously for five consecutive days in patients with advanced malignancies
TL;DR: It is concluded that the daily times five, q21 day schedule of BMS-214662 is safe at doses up to 81 mg/m2/day, but results in only transient inhibition of tissue FTase.
3
O-151 Phase II study of anatumomab mafenatox (ABR-214936) in advanced NSCLC: Results of a multi-institutinal open label repeat dose trial with patient-specific dose escalation
Corey J. Langer,R. Katherine Alpaugh,Francisco Robert,L. M. Weiner,Joan H. Schiller,M. Kopreski,Andre Rogatko,Göran Forsberg +7 more
1